Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2024

Open Access 01-12-2024 | Respiratory Syncytial Virus Infection | Systematic Review

Efficacy, immunogenicity and safety of respiratory syncytial virus prefusion F vaccine: systematic review and meta-analysis

Authors: Yi Pang, Haishan Lu, Demin Cao, Xiaoying Zhu, Qinqin Long, Fengqin Tian, Xidai Long, Yulei Li

Published in: BMC Public Health | Issue 1/2024

Login to get access

Abstract

Objective

A notable research gap exists in the systematic review and meta-analysis concerning the efficacy, immunogenicity, and safety of the respiratory syncytial virus (RSV) prefusion F vaccine.

Methods

We conducted a comprehensive search across PubMed, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov to retrieve articles related to the efficacy, immunogenicity, and safety of RSV prefusion F vaccines, published through September 8, 2023. We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

Results

A total of 22 randomized controlled trials involving 78,990 participants were included in this systematic review and meta-analysis. The RSV prefusion F vaccine exhibited a vaccine effectiveness of 68% (95% CI: 59–75%) against RSV-associated acute respiratory illness, 70% (95% CI: 60–77%) against medically attended RSV-associated lower respiratory tract illness, and 87% (95% CI: 71–94%) against medically attended severe RSV-associated lower respiratory tract illness. Common reported local adverse reactions following RSV prefusion F vaccination include pain, redness, and swelling at the injection site, and systemic reactions such as fatigue, headache, myalgia, arthralgia, nausea, and chills.

Conclusions

Our meta-analysis suggests that vaccines using the RSV prefusion F protein as antigen exhibit appears broadly acceptable efficacy, immunogenicity, and safety in the population. In particular, it provides high protective efficiency against severe RSV-associated lower respiratory tract disease.
Appendix
Available only for authorised users
Literature
1.
Langedijk AC, Bont LJ. Respiratory syncytial virus infection and novel interventions. Nat Rev Microbiol 2023.
2.
Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, Madhi SA, Omer SB, Simões EAF, Campbell H, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047–64.CrossRefPubMedPubMedCentral
3.
McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013;342(6158):592–8.CrossRefPubMedPubMedCentral
4.
Krarup A, Truan D, Furmanova-Hollenstein P, Bogaert L, Bouchier P, Bisschop IJM, Widjojoatmodjo MN, Zahn R, Schuitemaker H, McLellan JS, et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun. 2015;6:8143.CrossRefPubMed
5.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.CrossRefPubMedPubMedCentral
6.
Aliprantis AO, Shaw CA, Griffin P, Farinola N, Railkar RA, Cao X, Liu W, Sachs JR, Swenson CJ, Lee H, et al. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Hum Vaccines Immunotherapeutics. 2021;17(5):1248–61.CrossRef
7.
Baber J, Arya M, Moodley Y, Jaques A, Jiang Q, Swanson KA, Cooper D, Maddur MS, Loschko J, Gurtman A, et al. A phase 1/2 study of a respiratory Syncytial Virus Prefusion F Vaccine with and without adjuvant in healthy older adults. J Infect Dis. 2022;226(12):2054–63.CrossRefPubMedPubMedCentral
8.
Bebia Z, Reyes O, Jeanfreau R, Kantele A, De Leon RG, Sánchez MG, Banooni P, Gardener GJ, Rasero JLB, Pardilla MBE, et al. Safety and Immunogenicity of an investigational respiratory Syncytial Virus Vaccine (RSVPreF3) in mothers and their infants: a phase 2 Randomized Trial. J Infect Dis. 2023;228(3):299–310.CrossRefPubMedPubMedCentral
9.
Beran J, Lickliter JD, Schwarz TF, Johnson C, Chu L, Domachowske JB, Van Damme P, Withanage K, Fissette LA, David MP, et al. Safety and Immunogenicity of 3 formulations of an investigational respiratory Syncytial Virus Vaccine in Nonpregnant women: results from 2 phase 2 trials. J Infect Dis. 2018;217(10):1616–25.CrossRefPubMedPubMedCentral
10.
Comeaux CA, Bart S, Bastian AR, Klyashtornyy V, De Paepe E, Omoruyi E, van der Fits L, van Heesbeen R, Heijnen E, Callendret B et al. Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-based vaccine combinations: a Randomized, Double-blind, Placebo-Controlled, phase 1/2a study. J Infect Dis 2023.
11.
Falsey AR, Williams K, Gymnopoulou E, Bart S, Ervin J, Bastian AR, Menten J, De Paepe E, Vandenberghe S, Chan EKH, et al. Efficacy and safety of an Ad26.RSV.preF-RSV preF protein vaccine in older adults. N Engl J Med. 2023;388(7):609–20.CrossRefPubMed
12.
Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, Baker J, Pérez Marc G, Radley D, Shittu E, et al. Bivalent Prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451–64.CrossRefPubMed
13.
Kotb S, Haranaka M, Folschweiller N, Nakanwagi P, Verheust C, De Schrevel N, David MP, Mesaros N, Hulstrøm V. Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: a phase I, randomized, observer-blind clinical trial. Respiratory Invest. 2023;61(2):261–9.CrossRef
14.
Langley JM, Aggarwal N, Toma A, Halperin SA, McNeil SA, Fissette L, Dewé W, Leyssen M, Toussaint JF, Dieussaert I. A Randomized, Controlled, Observer-Blinded phase 1 study of the Safety and Immunogenicity of a respiratory Syncytial Virus Vaccine with or without Alum Adjuvant. J Infect Dis. 2017;215(1):24–33.CrossRefPubMed
15.
Leroux-Roels I, Davis MG, Steenackers K, Essink B, Vandermeulen C, Fogarty C, Andrews CP, Kerwin E, David MP, Fissette L, et al. Safety and Immunogenicity of a respiratory Syncytial Virus Prefusion F (RSVPreF3) candidate vaccine in older adults: phase 1/2 Randomized Clinical Trial. J Infect Dis. 2023;227(6):761–72.CrossRefPubMed
16.
Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, et al. Respiratory Syncytial Virus Prefusion F protein vaccine in older adults. N Engl J Med. 2023;388(7):595–608.CrossRefPubMed
17.
Peterson JT, Zareba AM, Fitz-Patrick D, Essink BJ, Scott DA, Swanson KA, Chelani D, Radley D, Cooper D, Jansen KU, et al. Safety and Immunogenicity of a respiratory Syncytial Virus Prefusion F Vaccine when Coadministered with a Tetanus, Diphtheria, and Acellular Pertussis Vaccine. J Infect Dis. 2022;225(12):2077–86.CrossRefPubMed
18.
Sadoff J, De Paepe E, DeVincenzo J, Gymnopoulou E, Menten J, Murray B, Rosemary Bastian A, Vandebosch A, Haazen W, Noulin N, et al. Prevention of respiratory syncytial virus infection in healthy adults by a single immunization of Ad26.RSV.preF in a human challenge study. J Infect Dis. 2022;226(3):396–406.CrossRefPubMed
19.
Sadoff J, De Paepe E, Haazen W, Omoruyi E, Bastian AR, Comeaux C, Heijnen E, Strout C, Schuitemaker H, Callendret B. Safety and Immunogenicity of the Ad26.RSV.preF investigational vaccine Coadministered with an Influenza Vaccine in older adults. J Infect Dis. 2021;223(4):699–708.CrossRefPubMed
20.
Schmoele-Thoma B, Zareba AM, Jiang Q, Maddur MS, Danaf R, Mann A, Eze K, Fok-Seang J, Kabir G, Catchpole A, et al. Vaccine efficacy in adults in a respiratory Syncytial Virus Challenge Study. N Engl J Med. 2022;386(25):2377–86.CrossRefPubMed
21.
Schwarz TF, Johnson C, Grigat C, Apter D, Csonka P, Lindblad N, Nguyen TL, Gao FF, Qian H, Tullio AN, et al. Three dose levels of a maternal respiratory syncytial virus vaccine candidate are well tolerated and immunogenic in a Randomized Trial in Nonpregnant Women. J Infect Dis. 2022;225(12):2067–76.CrossRefPubMed
22.
Schwarz TF, McPhee RA, Launay O, Leroux-Roels G, Talli J, Picciolato M, Gao F, Cai R, Nguyen TL, Dieussaert I, et al. Immunogenicity and safety of 3 formulations of a respiratory syncytial virus candidate vaccine in Nonpregnant women: a phase 2, Randomized Trial. J Infect Dis. 2019;220(11):1816–25.CrossRefPubMedPubMedCentral
23.
Simões EAF, Center KJ, Tita ATN, Swanson KA, Radley D, Houghton J, McGrory SB, Gomme E, Anderson M, Roberts JP, et al. Prefusion F protein-based respiratory Syncytial Virus immunization in pregnancy. N Engl J Med. 2022;386(17):1615–26.CrossRefPubMed
24.
Stuart A, Virta M, Williams K, Seppa I, Hartvickson R, Greenland M, Omoruyi E, Bastian AR, Haazen W, Salisch N et al. Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector RSV Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV Seropositive Children 12–24 Months. Journal of infectious diseases 2022.
25.
Walsh EE, Falsey AR, Scott DA, Gurtman A, Zareba AM, Jansen KU, Gruber WC, Dormitzer PR, Swanson KA, Radley D, et al. A Randomized Phase 1/2 study of a respiratory Syncytial Virus Prefusion F Vaccine. J Infect Dis. 2022;225(8):1357–66.CrossRefPubMed
26.
Walsh EE, Pérez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, Polack FP, Llapur C, Doreski PA, Ilangovan K, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med. 2023;388(16):1465–77.CrossRefPubMed
27.
Williams K, Bastian AR, Feldman RA, Omoruyi E, de Paepe E, Hendriks J, van Zeeburg H, Godeaux O, Langedijk JPM, Schuitemaker H, et al. Phase 1 safety and immunogenicity study of a respiratory Syncytial Virus Vaccine with an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in adults aged ≥ 60 years. J Infect Dis. 2020;222(6):979–88.CrossRefPubMed
28.
Falloon J, Yu J, Esser MT, Villafana T, Yu L, Dubovsky F, Takas T, Levin MJ, Falsey AR. An Adjuvanted, Postfusion F protein-based vaccine did not prevent respiratory Syncytial Virus illness in older adults. J Infect Dis. 2017;216(11):1362–70.CrossRefPubMedPubMedCentral
29.
Al-Sheboul SA, Brown B, Shboul Y, Fricke I, Imarogbe C, Alzoubi KH. An immunological review of SARS-CoV-2 infection and vaccine serology: innate and adaptive responses to mRNA, Adenovirus, inactivated and protein subunit vaccines. Vaccines 2022;11(1).
30.
McDonald I, Murray SM, Reynolds CJ, Altmann DM, Boyton RJ. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. NPJ Vaccines. 2021;6(1):74.CrossRefPubMedPubMedCentral
31.
32.
Al Khames Aga QA, Alkhaffaf WH, Hatem TH, Nassir KF, Batineh Y, Dahham AT, Shaban D, Al Khames Aga LA, Agha MYR, Traqchi M. Safety of COVID-19 vaccines. J Med Virol. 2021;93(12):6588–94.CrossRefPubMedPubMedCentral
33.
Fang E, Liu X, Li M, Zhang Z, Song L, Zhu B, Wu X, Liu J, Zhao D, Li Y. Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther. 2022;7(1):94.CrossRefPubMedPubMedCentral
34.
Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21(2):83–100.CrossRefPubMed
35.
Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, Eddins DL, Bryan JA. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol. 1979;110(2):105–23.CrossRefPubMed
36.
Chowdhury S, Chowdhury S. Association of Guillain-Barré syndrome following COVID-19 vaccination. Int J ImmunoPathol Pharmacol. 2023;37:3946320231199349.CrossRefPubMed
37.
Abara WE, Gee J, Marquez P, Woo J, Myers TR, DeSantis A, Baumblatt JAG, Woo EJ, Thompson D, Nair N, et al. Reports of Guillain-Barré Syndrome after COVID-19 vaccination in the United States. JAMA Netw Open. 2023;6(2):e2253845.CrossRefPubMedPubMedCentral
Metadata
Title
Efficacy, immunogenicity and safety of respiratory syncytial virus prefusion F vaccine: systematic review and meta-analysis
Authors
Yi Pang
Haishan Lu
Demin Cao
Xiaoying Zhu
Qinqin Long
Fengqin Tian
Xidai Long
Yulei Li
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2024
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-024-18748-8

Other articles of this Issue 1/2024

BMC Public Health 1/2024 Go to the issue

Research

A systematic review of parental burnout and related factors among parents

Research

Cooking behavior among mothers of children aged 2–5 years old in Kendari, Southeast Sulawesi, Indonesia

Research

Pregnancy health in a multi-state U.S. population of systemically underserved patients and their children: PROMISE cohort design and baseline characteristics

Research

A scoping review of wildfire smoke risk communications: issues, gaps, and recommendations

Research

Food insecurity in urban American Indian and Alaska Native populations during the COVID-19 pandemic

Research

Development and feasibility of a function-based preventive intervention for lifestyle-related disorders